 Amryt Pharma PLC AIM:AMYT, NASDAQ:AMYT has been boosted by positive trial results published by Lancet Diabetes Endocrinology. The company, in a statement, told investors that the full results of The global Phase 3 MPOWERED clinical trial compared Mycapssa, oral octreotide capsules, to long-acting injectable Somatostatin Receptor Ligands iSRLs for maintenance of biochemical response in patients with acromegaly. 